STR


Also found in: Dictionary, Thesaurus, Medical, Legal, Financial, Acronyms, Wikipedia.

STR

(control systems)

strike

1. In stone setting or bricklaying, to finish a mortar joint with a stroke of the trowel, simultaneously removing extruding mortar and smoothing the surface of the mortar remaining in the joint; strike off.

structural

Said of a load-bearing member, element, etc., of a building.
References in periodicals archive ?
Nepute John, 1500 KELLOGG RD; STR - single family residence; $214,354.
Nepute John, 1550 Kellogg Rd; STR - single family residence; $218,316.
Factors that could affect the Company's actual results include the availability of working capital and financing sources for the development of NeoRx's product candidates, the progress and costs of clinical trials and the timing of regulatory approvals, the availability of clinical materials from third-party suppliers, NeoRx's ability to manufacture STR in a timely and cost-effective manner, NeoRx's ability to successfully commercialize product candidates, and other risks and uncertainties described in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2003, and Quarterly Report on Form 10- Q for the quarter ended September 30, 2004.
NeoRx and STR are trademarks or registered trademarks of NeoRx Corporation in the United States and/or foreign countries.
Food and Drug Administration (FDA) for a Phase II clinical study of STR in patients with advanced breast cancer that has metastasized to the bone.
STR is composed of a bone-targeting molecule, DOTMP, in a stable complex with the radionuclide holmium-166.
NeoRx is developing STR for use with high-dose chemotherapy and autologous stem cell transplantation to treat multiple myeloma and other cancers where stem cell transplantation is indicated.
Factors that could affect the Company's actual results include conditions in the capital markets in general and in the life science sector in particular, specifically those that may affect potential financing sources for the development of NeoRx's business, the progress and costs of clinical trials and the timing of regulatory approvals, the availability of clinical materials from third-party suppliers, NeoRx's ability to manufacture STR in a timely and cost-effective manner and commercialize products, and other risks and uncertainties described in NeoRx's current and periodic reports filed with the Securities and Exchange Commission, including NeoRx's Annual Report on Form 10-K for the year ended December 31, 2003, and Quarterly Report on Form 10- Q for the quarter ended March 31, 2004.
Presently, NeoRx expects to file a New Drug Application (NDA) for STR in multiple myeloma in mid 2007.
The Company's lead therapeutic candidate, STR, is entering a phase III clinical trial in multiple myeloma, a cancer of the bone marrow.
NeoRx and STR are registered trademark of NeoRx Corporation in the United States and/or foreign countries.
The Company has stated previously that it expects to open the phase III trial of STR to patient enrollment in the first quarter of 2004, and plans to conduct the trial at approximately 40 clinical sites in the US and Canada.